Haemonetics stock heads into November 5 results after earnings beat

Published on 10/04/2026 at 21:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Haemonetics stock was last at USD 104.68 on October 2 after Q1 FY2027 revenue reached USD 339.38 million. The average analyst target is USD 99.78.

HAE, US4050241003, Illustration mit AI erstellt.

Haemonetics stock (ISIN US4050241003) was last at USD 104.68 on the NYSE on October 2, 2026, up USD 0.31 or 0.30 percent from the prior close. The company enters its next reporting date after Q1 FY2027 revenue reached USD 339.38 million, up 5.5 percent year over year, according to MarketBeat on October 2, 2026.

Revenue beat sets the baseline

Haemonetics also reported quarterly EPS of USD 1.14 against a USD 1.08 consensus estimate. Revenue exceeded the USD 327.86 million estimate, while the prior-year quarter produced revenue of USD 321.39 million and net profit of USD 34.03 million, compared with USD 33.01 million in the latest quarter, according to Markets Insider on October 1, 2026.

The combination is useful for reading the stock: sales growth remained positive, but net profit fell by USD 1.02 million year over year. That split makes the next margin update more important than the revenue figure alone.

Analysts see a lower average target

The analyst picture is constructive but less bullish than the share price. MarketBeat reported a Moderate Buy consensus from 11 covering brokerages, comprising six buys, four holds and one strong buy, with an average 12-month target of USD 99.78. That average sits USD 4.90 below the October 2 price, so the consensus does not imply additional upside at the quoted level.

Individual targets remain higher. Barrington maintained a Buy rating with a USD 118.00 target on October 1, while Citi had upgraded Haemonetics to Buy with a USD 123.00 target on September 18, as reported by Markets Insider. The spread between those targets and the average reflects a broad range of expectations rather than a single market view.

November results set the next test

Haemonetics plans to publish its Q2 FY2027 results at 6:00 a.m. ET on November 5, 2026, followed by an investor and analyst call at 8:00 a.m. ET, according to StockTitan. The release will test whether the 5.5 percent revenue increase can be paired with improved profitability after the latest net profit decline.

Haemonetics operates across plasma, blood center and hospital technologies. Its market value was USD 4.8 billion as of October 2, 2026, while the stock remained USD 5.77 below its USD 110.45 52-week high.

Stock remains below its yearly high

HAE was last at USD 104.68 on the NYSE on October 2, 2026, with volume of 328,573 shares and a 52-week range of USD 48.17 to USD 110.45. The next earnings date gives investors a defined checkpoint for judging revenue quality, profit conversion and the gap between the share price and the USD 99.78 consensus target.